This result is consistent with previous studies in CUP and non-CUP patients (Bochtler et al. 2020; Ricciuti et al. 2022), and may be attributed to the worse prognosis caused by KRAS mutations itself as well as the poorer response to ICIs due to changes in tumour microenvironment. Here, KRAS is linked to neoplasm.